Understanding MRI cT1’s Value in Liver Disease Care, with Rajarshi Banerjee, MD, PhD
Banerjee describes the value of multiorgan MRI for predicting cardiac and liver outcomes and cT1’s prognostic utility in liver disease.
Multiparametric MRI’s Cost-Effectiveness for MASH, with Rajarshi Banerjee, MD, PhD
Banerjee explains the need for noninvasive tests for MASH and reviews promising findings from the RADIcAL-1 trial of LiverMultiScan versus standard of care.
How New Therapies Change Discussions Around Screening, Management of MASH
In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.
Real-World MASH Populations Compared to MAESTRO-NASH
In part 4 of our 5-part video series, Arab and Banerjee discuss how the study population of MAESTRO-NASH compares to MASH populations in real-world settings.
Understanding Resmetirom's Potential Based on MAESTRO-NASH
In part 3 of our 5-part discussion, Arab and Banerjee dive into the results of the pivotal MAESTRO-NASH trial and how it can inform use of resmetirom in real-world settings.
Challenges, Recommendation Updates in Screening for MASH/MASLD
In part 2 of this 5-part video series, our experts in hepatology discuss the challenges, pitfalls, and recommendations for screening of MASH/MASLD in real-world settings.
Understanding NASH/NAFLD vs MASH/MASLD
In part 1 of this 5-part video series, our experts in hepatology discuss the recent change in nomenclature for NASH/NAFLD as compared to MASH/MASLD and how it effects management.
